GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

This study looks at whether a GLP-1 receptor agonist medication (a drug commonly used for type 2 diabetes and weight loss) can improve metabolic health and slow the progression of type 1 diabetes in people who are at an early stage — either pre-clinical stage 2 (no symptoms yet) or newly diagnosed stage 3. Some participants also receive teplizumab (an immune-modifying drug that delays type 1 diabetes onset). **You may be eligible if...** - You are 12 to 50 years old - You have stage 2 type 1 diabetes (2 or more diabetes-related antibodies plus specific blood sugar test results) OR early stage 3 type 1 diabetes (newly diagnosed within 8 weeks, HbA1c 5.7%–8.0%) - Your BMI is within the study range (18–31 for adults, 5th–95th percentile for children) **You may NOT be eligible if...** - You have high blood pressure, reduced kidney function, or significant liver disease - You have a family history of medullary thyroid cancer - You have had pancreatitis or gastroparesis in the past 3 years - You are taking diabetes medications, steroids, antipsychotics, certain blood pressure drugs, or oral contraceptives with higher estrogen levels - You are pregnant, post-menopausal, or an active smoker Talk to your doctor to see if this trial is right for you.